ArticlePloS one2015
The Clinical Effectiveness and Cost-Effectiveness of Screening for Age-Related Macular Degeneration in Japan: A Markov Modeling Study.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 40 citations in OpenAlex.
- Backflow reduction in local injection therapy with gelatin formulations.Drug delivery · 2024Article
- Application of Artificial Intelligence Models to Predict the Onset or Recurrence of Neovascular Age-Related Macular Degeneration.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Fundus Image Deep Learning Study to Explore the Association of Retinal Morphology with Age-Related Macular Degeneration Polygenic Risk Score.Biomedicines · 2024Article
- Multiplexed plasma protein classifiers for the diagnosis of age-related macular degeneration.Clinical and translational medicine · 2023Article
- Cost-effectiveness analysis of artificial intelligence-based diabetic retinopathy screening in rural China based on the Markov model.PloS one · 2023Article
- Synthetic artificial intelligence using generative adversarial network for retinal imaging in detection of age-related macular degeneration.Frontiers in medicine · 2023Article
- Cost-effectiveness and cost-utility of traditional and telemedicine combined population-based age-related macular degeneration and diabetic retinopathy screening in rural and urban China.The Lancet regional health. Western Pacific · 2022Article
- Telemedicine for the Diagnosis and Management of Age-Related Macular Degeneration: A Review.Journal of clinical medicine · 2022Review
- Real-world effectiveness of screening programs for age-related macular degeneration: amended Japanese specific health checkups and augmented screening programs with OCT or AI.Japanese journal of ophthalmology · 2022Article
- Self-sealing hyaluronic acid-coated 30-gauge intravitreal injection needles for preventing vitreous and drug reflux through needle passage.Scientific reports · 2021Article
- Higher Participation Rate for Specific Health Checkups Concerning Simultaneous Ophthalmic Checkups.Journal of epidemiology · 2021Article
- Telemedicine for Age-Related Macular Degeneration.Telemedicine journal and e-health : the official journal of the American Telemedicine Association · 2020Review
- Practice Guidelines for Ocular Telehealth-Diabetic Retinopathy, Third Edition.Telemedicine journal and e-health : the official journal of the American Telemedicine Association · 2020Article
- Detection of Glaucoma and Other Vision-Threatening Ocular Diseases in the Population Recruited at Specific Health Checkups in Japan.Clinical epidemiology · 2020Article
- Vision-related quality of life in Japanese patients with wet age-related macular degeneration treated with intravitreal aflibercept in a real-world setting.Japanese journal of ophthalmology · 2019Observational
- Evaluation of a Remote Diagnosis Imaging Model vs Dilated Eye Examination in Referable Macular Degeneration.JAMA ophthalmology · 2019Article
- Cost-effectiveness of age-related macular degeneration study supplements in the UK: combined trial and real-world outcomes data.The British journal of ophthalmology · 2018Article
- The cost-effectiveness of systematic screening for age-related macular degeneration in South Korea.PloS one · 2018Article
- Incidence of Referable Retinal Disease in Diabetic Patients at a Primary Care Practice.Journal of vitreoretinal diseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the cost-effectiveness of screening and subsequent intervention for age-related macular degeneration (AMD) in Japan.
methodsThe clinical effectiveness and cost-effectiveness of screening and subsequent intervention for AMD were assessed using a Markov model. The Markov model simulation began at the age of 40 years and concluded at the age of 90 years. The first-eye and second-eye combined model assumed an annual state-transition probability, development of prodromal symptoms, choroidal neovascularization (CNV), and reduction in visual acuity. Anti-vascular-endothelial-growth-factor (anti-VEGF) intravitreal injection therapy and photodynamic therapy (PDT) were performed to treat CNV. Intake of supplements was recommended to patients who had prodromal symptoms and unilateral AMD. Data on prevalence, morbidity, transition probability, utility value of each AMD patient, and treatment costs were obtained from published clinical reports.
resultsIn the base-case analysis, screening for AMD every 5 years, beginning at the age of 50 years, showed a decrease of 41% in the total number of blind patients. The screening program reduced the incidence of blindness more than did the additional intake of supplements. However, the incremental cost-effectiveness ratio (ICER) of screening versus no screening was 27,486,352 Japanese yen (JPY), or 259,942 US dollars (USD) per quality-adjusted life year (QALY). In the sensitivity analysis, prodromal symptom-related factors for AMD had great impacts on the cost-effectiveness of screening. The lowest ICER obtained from the best scenario was 4,913,717 JPY (46,470 USD) per QALY, which was approximately equal to the willingness to pay in Japan.
conclusionsOphthalmologic screening for AMD in adults is highly effective in reducing the number of patients with blindness but not cost-effective as demonstrated by a Markov model based on clinical data from Japan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.